pyrimidinones and Nocturnal-Enuresis

Long-term nocturnal enuresis treatment leads to stress and lowered self-esteem for children and their parents. This study evaluated the short-term effectiveness and safety of vibegron (50 mg) for children with refractory nocturnal enuresis.. A retrospective cohort study of children with therapy-resistant enuresis was conducted using data for July to December 2019. Enuresis frequency was recorded during 30 days before and after additional vibegron administration with prior treatment. We assessed the treatment effectiveness based on enuresis frequencies between before and after treatment with vibegron 50 mg. Statistical evaluation was performed using a paired t-test.. Among 29 children receiving vibegron, 14 (48.3%) exhibited a partial or complete response to the drug. Enuresis frequencies (mean ± standard deviation [SD]) were, respectively, 15.8 ± 9.2 and 9.5 ± 9.6 before and after treatment with vibegron during the observed 30 days. A statistically significant reduction in enuresis frequency was found (p < 0.001). Moreover, maximum mean±SD morning urine of 200 ± 62.9 mL before treatment with vibegron changed to 232 ± 76.6 mL after treatment. A significant increase in voiding volume in the early morning was found (p < 0.05). No drug-related severe adverse event was found.. Short-term treatment with vibegron is safe and effective for children with refractory enuresis.

Topics: Child; Humans; Nocturnal Enuresis; Pyrimidinones; Pyrrolidines; Retrospective Studies; Treatment Outcome; Urinary Incontinence

Topics: Deamino Arginine Vasopressin; Humans; Nocturnal Enuresis; Pyrimidinones; Pyrrolidines; Solifenacin Succinate

Topics: Adrenergic beta-3 Receptor Agonists; Child; Enuresis; Humans; Nocturnal Enuresis; Pyrimidinones; Pyrrolidines

Topics: Adrenergic beta-3 Receptor Agonists; Child; Humans; Nocturnal Enuresis; Pyrimidinones; Pyrrolidines